Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19

Piovezan et al., NCT04470297, MELCOV2020, NCT04470297, Mar 2021

Melatonin for COVID-19

11th treatment shown to reduce risk in December 2020, now with p = 0.000000011 from 20 studies.

Lower risk for mortality, ventilation, and recovery.

No treatment is 100% effective. Protocols combine treatments.

6,300+ studies for 210+ treatments. c19early.org

Meta Analysis

Estimated 100 patient melatonin late treatment RCT with results not reported over 4 years after estimated completion.

3 melatonin RCTs have results missing long after expected1-3
The trials report a total of 268 patients, with 2 trials having actual enrollment of 168, and the other estimated.

Important missing comments or errors? Let us know.

1. Boukef et al., Melatonin, Vitamins and Minerals Supplements for the Treatment of Covid-19 and Covid-like Illness: Results of a Prospective, Randomised, Double-blinded Multicentre Study, NCT05670444, clinicaltrials.gov/study/NCT05670444clinicaltrials.gov.

2. Piovezan et al., Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19, NCT04470297, clinicaltrials.gov/study/NCT04470297clinicaltrials.gov.

3. Rodríguez-Rubio et al., A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial, Trials, doi:10.1186/s13063-020-04632-4.biomedcentral.com, doi.org.

Piovezan et al., 1 Mar 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Brazil, trial NCT04470297 (history) (MELCOV2020). Contact: rdpiovezan@gmail.com.

Late treatment
is less effective